44 results
424B5
PRTG
Portage Biotech Inc
2 Oct 23
Prospectus supplement for primary offering
6:01pm
or non-small cell lung carcinoma (NSCLC) in order to evaluate the safety and efficacy after receiving regulatory approval from the Medicines and Healthcare
6-K
EX-99.1
j5jyt
7 Oct 22
Notice of Annual General Meeting
3:06pm
6-K
EX-99.1
09ov9hcmu332o
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.2
b394wzoybn
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.2
vm7rfgl63zdv 8bnt035
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.1
112h66es4 yu
23 Nov 21
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.2
sqnmp
30 Aug 21
Current report (foreign)
5:21pm
6-K
EX-99.1
2vapd8ihfmw
30 Aug 21
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
8:00am
SUPPL
ypr2meeq
24 Jun 21
Supplemental materials (foreign)
5:27pm
6-K
EX-1.1
v08ywv0cxhogjbw7d0i
24 Jun 21
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
4:05pm
SUPPL
4x5gr9hbea8y x8
23 Jun 21
Supplemental materials (foreign)
4:01pm
424B2
r6yfbn6pdsw4su5
8 Mar 21
Prospectus for primary offering
5:00pm
6-K
EX-99.2
dp6n oj2tvlf
1 Mar 21
Condensed Consolidated Interim Financial Statements
4:23pm
F-3
r4i08tomgoeytgqt
24 Feb 21
Shelf registration (foreign)
5:22pm